Viral Testing Comprehensive Study by Type (Direct Fluorescent Antibody (DFA) Test, Immunochromatographic Assay, RT-PCR-Based Test, Agglutination Assay, Flow-Through Assay/Solid-Phase Assay), Application (Individual, Commercial), End-User (Laboratories, Hospitals, Home Care Settings, Academic Institutes), Virus Type (Influenza, Hepatitis, HIV, Measles, Rubella, Others) Players and Region - Global Market Outlook to 2025

Report Objectives / Segmentation Covered

• Direct Fluorescent Antibody (DFA) Test
• Immunochromatographic Assay
• RT-PCR-Based Test
• Agglutination Assay
• Flow-Through Assay/Solid-Phase Assay

• Individual
• Commercial

• Laboratories
• Hospitals
• Home Care Settings
• Academic Institutes

• Influenza
• Hepatitis
• HIV
• Measles
• Rubella
• Others

• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Taiwan
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • Italy
  • United Kingdom
  • Netherlands
  • Rest of Europe
• MEA
  • Middle East
  • Africa
• North America
  • United States
  • Canada
  • Mexico

• 1. Market Overview
  • 1.1. Introduction
  • 1.2. Scope/Objective of the Study
    • 1.2.1. Research Objective
• 2. Executive Summary
  • 2.1. Introduction
• 3. Market Dynamics
  • 3.1. Introduction
  • 3.2. Market Drivers
    • 3.2.1. Rising Prevalence of the Disease across the Globe
    • 3.2.2. Increasing Demand for More Rapid Diagnostic Test Kits for Influenza
    • 3.2.3. Rising Prevalence of Viral Diseases
  • 3.3. Market Challenges
    • 3.3.1. Unawareness about Viral Testing in Under Developed Regions
  • 3.4. Market Trends
    • 3.4.1. Emergence and Detection of New Viruses
    • 3.4.2. Rising Adoption of Self-Diagnostic and Cost-Effective Test Kits by Patients As Well As Physicians
• 4. Market Factor Analysis
  • 4.1. Porters Five Forces
  • 4.2. Supply/Value Chain
  • 4.3. PESTEL analysis
  • 4.4. Market Entropy
  • 4.5. Patent/Trademark Analysis
• 5. Global Viral Testing, by Type, Application, End-User, Virus Type and Region (value, volume and price ) (2014-2019)
  • 5.1. Introduction
  • 5.2. Global Viral Testing (Value)
    • 5.2.1. Global Viral Testing by: Type (Value)
      • 5.2.1.1. Direct Fluorescent Antibody (DFA) Test
      • 5.2.1.2. Immunochromatographic Assay
      • 5.2.1.3. RT-PCR-Based Test
      • 5.2.1.4. Agglutination Assay
      • 5.2.1.5. Flow-Through Assay/Solid-Phase Assay
    • 5.2.2. Global Viral Testing by: Application (Value)
      • 5.2.2.1. Individual
      • 5.2.2.2. Commercial
    • 5.2.3. Global Viral Testing by: End-User (Value)
      • 5.2.3.1. Laboratories
      • 5.2.3.2. Hospitals
      • 5.2.3.3. Home Care Settings
      • 5.2.3.4. Academic Institutes
    • 5.2.4. Global Viral Testing by: Virus Type (Value)
      • 5.2.4.1. Influenza
      • 5.2.4.2. Hepatitis
      • 5.2.4.3. HIV
      • 5.2.4.4. Measles
      • 5.2.4.5. Rubella
      • 5.2.4.6. Others
    • 5.2.5. Global Viral Testing Region
      • 5.2.5.1. South America
        • 5.2.5.1.1. Brazil
        • 5.2.5.1.2. Argentina
        • 5.2.5.1.3. Rest of South America
      • 5.2.5.2. Asia Pacific
        • 5.2.5.2.1. China
        • 5.2.5.2.2. Japan
        • 5.2.5.2.3. India
        • 5.2.5.2.4. South Korea
        • 5.2.5.2.5. Taiwan
        • 5.2.5.2.6. Australia
        • 5.2.5.2.7. Rest of Asia-Pacific
      • 5.2.5.3. Europe
        • 5.2.5.3.1. Germany
        • 5.2.5.3.2. France
        • 5.2.5.3.3. Italy
        • 5.2.5.3.4. United Kingdom
        • 5.2.5.3.5. Netherlands
        • 5.2.5.3.6. Rest of Europe
      • 5.2.5.4. MEA
        • 5.2.5.4.1. Middle East
        • 5.2.5.4.2. Africa
      • 5.2.5.5. North America
        • 5.2.5.5.1. United States
        • 5.2.5.5.2. Canada
        • 5.2.5.5.3. Mexico
  • 5.3. Global Viral Testing (Volume)
    • 5.3.1. Global Viral Testing by: Type (Volume)
      • 5.3.1.1. Direct Fluorescent Antibody (DFA) Test
      • 5.3.1.2. Immunochromatographic Assay
      • 5.3.1.3. RT-PCR-Based Test
      • 5.3.1.4. Agglutination Assay
      • 5.3.1.5. Flow-Through Assay/Solid-Phase Assay
    • 5.3.2. Global Viral Testing by: Application (Volume)
      • 5.3.2.1. Individual
      • 5.3.2.2. Commercial
    • 5.3.3. Global Viral Testing by: End-User (Volume)
      • 5.3.3.1. Laboratories
      • 5.3.3.2. Hospitals
      • 5.3.3.3. Home Care Settings
      • 5.3.3.4. Academic Institutes
    • 5.3.4. Global Viral Testing by: Virus Type (Volume)
      • 5.3.4.1. Influenza
      • 5.3.4.2. Hepatitis
      • 5.3.4.3. HIV
      • 5.3.4.4. Measles
      • 5.3.4.5. Rubella
      • 5.3.4.6. Others
    • 5.3.5. Global Viral Testing Region
      • 5.3.5.1. South America
        • 5.3.5.1.1. Brazil
        • 5.3.5.1.2. Argentina
        • 5.3.5.1.3. Rest of South America
      • 5.3.5.2. Asia Pacific
        • 5.3.5.2.1. China
        • 5.3.5.2.2. Japan
        • 5.3.5.2.3. India
        • 5.3.5.2.4. South Korea
        • 5.3.5.2.5. Taiwan
        • 5.3.5.2.6. Australia
        • 5.3.5.2.7. Rest of Asia-Pacific
      • 5.3.5.3. Europe
        • 5.3.5.3.1. Germany
        • 5.3.5.3.2. France
        • 5.3.5.3.3. Italy
        • 5.3.5.3.4. United Kingdom
        • 5.3.5.3.5. Netherlands
        • 5.3.5.3.6. Rest of Europe
      • 5.3.5.4. MEA
        • 5.3.5.4.1. Middle East
        • 5.3.5.4.2. Africa
      • 5.3.5.5. North America
        • 5.3.5.5.1. United States
        • 5.3.5.5.2. Canada
        • 5.3.5.5.3. Mexico
  • 5.4. Global Viral Testing (Price)
    • 5.4.1. Global Viral Testing by: Type (Price)
• 6. Viral Testing: Manufacturers/Players Analysis
  • 6.1. Competitive Landscape
    • 6.1.1. Market Share Analysis
      • 6.1.1.1. Top 3
      • 6.1.1.2. Top 5
  • 6.2. Peer Group Analysis (2019)
  • 6.3. BCG Matrix
  • 6.4. Company Profile
    • 6.4.1. Roche Holding AG (Switzerland)
      • 6.4.1.1. Business Overview
      • 6.4.1.2. Products/Services Offerings
      • 6.4.1.3. Financial Analysis
      • 6.4.1.4. SWOT Analysis
    • 6.4.2. Agilent Technologies (United States)
      • 6.4.2.1. Business Overview
      • 6.4.2.2. Products/Services Offerings
      • 6.4.2.3. Financial Analysis
      • 6.4.2.4. SWOT Analysis
    • 6.4.3. Thermo Fisher Scientific (United States)
      • 6.4.3.1. Business Overview
      • 6.4.3.2. Products/Services Offerings
      • 6.4.3.3. Financial Analysis
      • 6.4.3.4. SWOT Analysis
    • 6.4.4. QIAGEN International (Netherlands)
      • 6.4.4.1. Business Overview
      • 6.4.4.2. Products/Services Offerings
      • 6.4.4.3. Financial Analysis
      • 6.4.4.4. SWOT Analysis
    • 6.4.5. Lonza Group AG (Switzerland)
      • 6.4.5.1. Business Overview
      • 6.4.5.2. Products/Services Offerings
      • 6.4.5.3. Financial Analysis
      • 6.4.5.4. SWOT Analysis
    • 6.4.6. Wuxi Pharmatech (Cayman)
      • 6.4.6.1. Business Overview
      • 6.4.6.2. Products/Services Offerings
      • 6.4.6.3. Financial Analysis
      • 6.4.6.4. SWOT Analysis
    • 6.4.7. Merck (United States)
      • 6.4.7.1. Business Overview
      • 6.4.7.2. Products/Services Offerings
      • 6.4.7.3. Financial Analysis
      • 6.4.7.4. SWOT Analysis
    • 6.4.8. Eurofins Scientific (Luxembourg)
      • 6.4.8.1. Business Overview
      • 6.4.8.2. Products/Services Offerings
      • 6.4.8.3. Financial Analysis
      • 6.4.8.4. SWOT Analysis
    • 6.4.9. General Electric (United States)
      • 6.4.9.1. Business Overview
      • 6.4.9.2. Products/Services Offerings
      • 6.4.9.3. Financial Analysis
      • 6.4.9.4. SWOT Analysis
    • 6.4.10. Danaher Corporation (United States)
      • 6.4.10.1. Business Overview
      • 6.4.10.2. Products/Services Offerings
      • 6.4.10.3. Financial Analysis
      • 6.4.10.4. SWOT Analysis
    • 6.4.11. Bio-Rad Laboratories (United States)
      • 6.4.11.1. Business Overview
      • 6.4.11.2. Products/Services Offerings
      • 6.4.11.3. Financial Analysis
      • 6.4.11.4. SWOT Analysis
    • 6.4.12. BD (United States)
      • 6.4.12.1. Business Overview
      • 6.4.12.2. Products/Services Offerings
      • 6.4.12.3. Financial Analysis
      • 6.4.12.4. SWOT Analysis
• 7. Global Viral Testing Sale, by Type, Application, End-User, Virus Type and Region (value, volume and price ) (2020-2025)
  • 7.1. Introduction
  • 7.2. Global Viral Testing (Value)
    • 7.2.1. Global Viral Testing by: Type (Value)
      • 7.2.1.1. Direct Fluorescent Antibody (DFA) Test
      • 7.2.1.2. Immunochromatographic Assay
      • 7.2.1.3. RT-PCR-Based Test
      • 7.2.1.4. Agglutination Assay
      • 7.2.1.5. Flow-Through Assay/Solid-Phase Assay
    • 7.2.2. Global Viral Testing by: Application (Value)
      • 7.2.2.1. Individual
      • 7.2.2.2. Commercial
    • 7.2.3. Global Viral Testing by: End-User (Value)
      • 7.2.3.1. Laboratories
      • 7.2.3.2. Hospitals
      • 7.2.3.3. Home Care Settings
      • 7.2.3.4. Academic Institutes
    • 7.2.4. Global Viral Testing by: Virus Type (Value)
      • 7.2.4.1. Influenza
      • 7.2.4.2. Hepatitis
      • 7.2.4.3. HIV
      • 7.2.4.4. Measles
      • 7.2.4.5. Rubella
      • 7.2.4.6. Others
    • 7.2.5. Global Viral Testing Region
      • 7.2.5.1. South America
        • 7.2.5.1.1. Brazil
        • 7.2.5.1.2. Argentina
        • 7.2.5.1.3. Rest of South America
      • 7.2.5.2. Asia Pacific
        • 7.2.5.2.1. China
        • 7.2.5.2.2. Japan
        • 7.2.5.2.3. India
        • 7.2.5.2.4. South Korea
        • 7.2.5.2.5. Taiwan
        • 7.2.5.2.6. Australia
        • 7.2.5.2.7. Rest of Asia-Pacific
      • 7.2.5.3. Europe
        • 7.2.5.3.1. Germany
        • 7.2.5.3.2. France
        • 7.2.5.3.3. Italy
        • 7.2.5.3.4. United Kingdom
        • 7.2.5.3.5. Netherlands
        • 7.2.5.3.6. Rest of Europe
      • 7.2.5.4. MEA
        • 7.2.5.4.1. Middle East
        • 7.2.5.4.2. Africa
      • 7.2.5.5. North America
        • 7.2.5.5.1. United States
        • 7.2.5.5.2. Canada
        • 7.2.5.5.3. Mexico
  • 7.3. Global Viral Testing (Volume)
    • 7.3.1. Global Viral Testing by: Type (Volume)
      • 7.3.1.1. Direct Fluorescent Antibody (DFA) Test
      • 7.3.1.2. Immunochromatographic Assay
      • 7.3.1.3. RT-PCR-Based Test
      • 7.3.1.4. Agglutination Assay
      • 7.3.1.5. Flow-Through Assay/Solid-Phase Assay
    • 7.3.2. Global Viral Testing by: Application (Volume)
      • 7.3.2.1. Individual
      • 7.3.2.2. Commercial
    • 7.3.3. Global Viral Testing by: End-User (Volume)
      • 7.3.3.1. Laboratories
      • 7.3.3.2. Hospitals
      • 7.3.3.3. Home Care Settings
      • 7.3.3.4. Academic Institutes
    • 7.3.4. Global Viral Testing by: Virus Type (Volume)
      • 7.3.4.1. Influenza
      • 7.3.4.2. Hepatitis
      • 7.3.4.3. HIV
      • 7.3.4.4. Measles
      • 7.3.4.5. Rubella
      • 7.3.4.6. Others
    • 7.3.5. Global Viral Testing Region
      • 7.3.5.1. South America
        • 7.3.5.1.1. Brazil
        • 7.3.5.1.2. Argentina
        • 7.3.5.1.3. Rest of South America
      • 7.3.5.2. Asia Pacific
        • 7.3.5.2.1. China
        • 7.3.5.2.2. Japan
        • 7.3.5.2.3. India
        • 7.3.5.2.4. South Korea
        • 7.3.5.2.5. Taiwan
        • 7.3.5.2.6. Australia
        • 7.3.5.2.7. Rest of Asia-Pacific
      • 7.3.5.3. Europe
        • 7.3.5.3.1. Germany
        • 7.3.5.3.2. France
        • 7.3.5.3.3. Italy
        • 7.3.5.3.4. United Kingdom
        • 7.3.5.3.5. Netherlands
        • 7.3.5.3.6. Rest of Europe
      • 7.3.5.4. MEA
        • 7.3.5.4.1. Middle East
        • 7.3.5.4.2. Africa
      • 7.3.5.5. North America
        • 7.3.5.5.1. United States
        • 7.3.5.5.2. Canada
        • 7.3.5.5.3. Mexico
  • 7.4. Global Viral Testing (Price)
    • 7.4.1. Global Viral Testing by: Type (Price)
• 8. Appendix
  • 8.1. Acronyms
• 9. Methodology and Data Source
  • 9.1. Methodology/Research Approach
    • 9.1.1. Research Programs/Design
    • 9.1.2. Market Size Estimation
    • 9.1.3. Market Breakdown and Data Triangulation
  • 9.2. Data Source
    • 9.2.1. Secondary Sources
    • 9.2.2. Primary Sources
  • 9.3. Disclaimer

• Table 1. Viral Testing: by Type(USD Million)
• Table 2. Viral Testing Direct Fluorescent Antibody (DFA) Test , by Region USD Million (2014-2019)
• Table 3. Viral Testing Immunochromatographic Assay , by Region USD Million (2014-2019)
• Table 4. Viral Testing RT-PCR-Based Test , by Region USD Million (2014-2019)
• Table 5. Viral Testing Agglutination Assay , by Region USD Million (2014-2019)
• Table 6. Viral Testing Flow-Through Assay/Solid-Phase Assay , by Region USD Million (2014-2019)
• Table 7. Viral Testing: by Application(USD Million)
• Table 8. Viral Testing Individual , by Region USD Million (2014-2019)
• Table 9. Viral Testing Commercial , by Region USD Million (2014-2019)
• Table 10. Viral Testing: by End-User(USD Million)
• Table 11. Viral Testing Laboratories , by Region USD Million (2014-2019)
• Table 12. Viral Testing Hospitals , by Region USD Million (2014-2019)
• Table 13. Viral Testing Home Care Settings , by Region USD Million (2014-2019)
• Table 14. Viral Testing Academic Institutes , by Region USD Million (2014-2019)
• Table 15. Viral Testing: by Virus Type(USD Million)
• Table 16. Viral Testing Influenza , by Region USD Million (2014-2019)
• Table 17. Viral Testing Hepatitis , by Region USD Million (2014-2019)
• Table 18. Viral Testing HIV , by Region USD Million (2014-2019)
• Table 19. Viral Testing Measles , by Region USD Million (2014-2019)
• Table 20. Viral Testing Rubella , by Region USD Million (2014-2019)
• Table 21. Viral Testing Others , by Region USD Million (2014-2019)
• Table 22. South America Viral Testing, by Country USD Million (2014-2019)
• Table 23. South America Viral Testing, by Type USD Million (2014-2019)
• Table 24. South America Viral Testing, by Application USD Million (2014-2019)
• Table 25. South America Viral Testing, by End-User USD Million (2014-2019)
• Table 26. South America Viral Testing, by Virus Type USD Million (2014-2019)
• Table 27. Brazil Viral Testing, by Type USD Million (2014-2019)
• Table 28. Brazil Viral Testing, by Application USD Million (2014-2019)
• Table 29. Brazil Viral Testing, by End-User USD Million (2014-2019)
• Table 30. Brazil Viral Testing, by Virus Type USD Million (2014-2019)
• Table 31. Argentina Viral Testing, by Type USD Million (2014-2019)
• Table 32. Argentina Viral Testing, by Application USD Million (2014-2019)
• Table 33. Argentina Viral Testing, by End-User USD Million (2014-2019)
• Table 34. Argentina Viral Testing, by Virus Type USD Million (2014-2019)
• Table 35. Rest of South America Viral Testing, by Type USD Million (2014-2019)
• Table 36. Rest of South America Viral Testing, by Application USD Million (2014-2019)
• Table 37. Rest of South America Viral Testing, by End-User USD Million (2014-2019)
• Table 38. Rest of South America Viral Testing, by Virus Type USD Million (2014-2019)
• Table 39. Asia Pacific Viral Testing, by Country USD Million (2014-2019)
• Table 40. Asia Pacific Viral Testing, by Type USD Million (2014-2019)
• Table 41. Asia Pacific Viral Testing, by Application USD Million (2014-2019)
• Table 42. Asia Pacific Viral Testing, by End-User USD Million (2014-2019)
• Table 43. Asia Pacific Viral Testing, by Virus Type USD Million (2014-2019)
• Table 44. China Viral Testing, by Type USD Million (2014-2019)
• Table 45. China Viral Testing, by Application USD Million (2014-2019)
• Table 46. China Viral Testing, by End-User USD Million (2014-2019)
• Table 47. China Viral Testing, by Virus Type USD Million (2014-2019)
• Table 48. Japan Viral Testing, by Type USD Million (2014-2019)
• Table 49. Japan Viral Testing, by Application USD Million (2014-2019)
• Table 50. Japan Viral Testing, by End-User USD Million (2014-2019)
• Table 51. Japan Viral Testing, by Virus Type USD Million (2014-2019)
• Table 52. India Viral Testing, by Type USD Million (2014-2019)
• Table 53. India Viral Testing, by Application USD Million (2014-2019)
• Table 54. India Viral Testing, by End-User USD Million (2014-2019)
• Table 55. India Viral Testing, by Virus Type USD Million (2014-2019)
• Table 56. South Korea Viral Testing, by Type USD Million (2014-2019)
• Table 57. South Korea Viral Testing, by Application USD Million (2014-2019)
• Table 58. South Korea Viral Testing, by End-User USD Million (2014-2019)
• Table 59. South Korea Viral Testing, by Virus Type USD Million (2014-2019)
• Table 60. Taiwan Viral Testing, by Type USD Million (2014-2019)
• Table 61. Taiwan Viral Testing, by Application USD Million (2014-2019)
• Table 62. Taiwan Viral Testing, by End-User USD Million (2014-2019)
• Table 63. Taiwan Viral Testing, by Virus Type USD Million (2014-2019)
• Table 64. Australia Viral Testing, by Type USD Million (2014-2019)
• Table 65. Australia Viral Testing, by Application USD Million (2014-2019)
• Table 66. Australia Viral Testing, by End-User USD Million (2014-2019)
• Table 67. Australia Viral Testing, by Virus Type USD Million (2014-2019)
• Table 68. Rest of Asia-Pacific Viral Testing, by Type USD Million (2014-2019)
• Table 69. Rest of Asia-Pacific Viral Testing, by Application USD Million (2014-2019)
• Table 70. Rest of Asia-Pacific Viral Testing, by End-User USD Million (2014-2019)
• Table 71. Rest of Asia-Pacific Viral Testing, by Virus Type USD Million (2014-2019)
• Table 72. Europe Viral Testing, by Country USD Million (2014-2019)
• Table 73. Europe Viral Testing, by Type USD Million (2014-2019)
• Table 74. Europe Viral Testing, by Application USD Million (2014-2019)
• Table 75. Europe Viral Testing, by End-User USD Million (2014-2019)
• Table 76. Europe Viral Testing, by Virus Type USD Million (2014-2019)
• Table 77. Germany Viral Testing, by Type USD Million (2014-2019)
• Table 78. Germany Viral Testing, by Application USD Million (2014-2019)
• Table 79. Germany Viral Testing, by End-User USD Million (2014-2019)
• Table 80. Germany Viral Testing, by Virus Type USD Million (2014-2019)
• Table 81. France Viral Testing, by Type USD Million (2014-2019)
• Table 82. France Viral Testing, by Application USD Million (2014-2019)
• Table 83. France Viral Testing, by End-User USD Million (2014-2019)
• Table 84. France Viral Testing, by Virus Type USD Million (2014-2019)
• Table 85. Italy Viral Testing, by Type USD Million (2014-2019)
• Table 86. Italy Viral Testing, by Application USD Million (2014-2019)
• Table 87. Italy Viral Testing, by End-User USD Million (2014-2019)
• Table 88. Italy Viral Testing, by Virus Type USD Million (2014-2019)
• Table 89. United Kingdom Viral Testing, by Type USD Million (2014-2019)
• Table 90. United Kingdom Viral Testing, by Application USD Million (2014-2019)
• Table 91. United Kingdom Viral Testing, by End-User USD Million (2014-2019)
• Table 92. United Kingdom Viral Testing, by Virus Type USD Million (2014-2019)
• Table 93. Netherlands Viral Testing, by Type USD Million (2014-2019)
• Table 94. Netherlands Viral Testing, by Application USD Million (2014-2019)
• Table 95. Netherlands Viral Testing, by End-User USD Million (2014-2019)
• Table 96. Netherlands Viral Testing, by Virus Type USD Million (2014-2019)
• Table 97. Rest of Europe Viral Testing, by Type USD Million (2014-2019)
• Table 98. Rest of Europe Viral Testing, by Application USD Million (2014-2019)
• Table 99. Rest of Europe Viral Testing, by End-User USD Million (2014-2019)
• Table 100. Rest of Europe Viral Testing, by Virus Type USD Million (2014-2019)
• Table 101. MEA Viral Testing, by Country USD Million (2014-2019)
• Table 102. MEA Viral Testing, by Type USD Million (2014-2019)
• Table 103. MEA Viral Testing, by Application USD Million (2014-2019)
• Table 104. MEA Viral Testing, by End-User USD Million (2014-2019)
• Table 105. MEA Viral Testing, by Virus Type USD Million (2014-2019)
• Table 106. Middle East Viral Testing, by Type USD Million (2014-2019)
• Table 107. Middle East Viral Testing, by Application USD Million (2014-2019)
• Table 108. Middle East Viral Testing, by End-User USD Million (2014-2019)
• Table 109. Middle East Viral Testing, by Virus Type USD Million (2014-2019)
• Table 110. Africa Viral Testing, by Type USD Million (2014-2019)
• Table 111. Africa Viral Testing, by Application USD Million (2014-2019)
• Table 112. Africa Viral Testing, by End-User USD Million (2014-2019)
• Table 113. Africa Viral Testing, by Virus Type USD Million (2014-2019)
• Table 114. North America Viral Testing, by Country USD Million (2014-2019)
• Table 115. North America Viral Testing, by Type USD Million (2014-2019)
• Table 116. North America Viral Testing, by Application USD Million (2014-2019)
• Table 117. North America Viral Testing, by End-User USD Million (2014-2019)
• Table 118. North America Viral Testing, by Virus Type USD Million (2014-2019)
• Table 119. United States Viral Testing, by Type USD Million (2014-2019)
• Table 120. United States Viral Testing, by Application USD Million (2014-2019)
• Table 121. United States Viral Testing, by End-User USD Million (2014-2019)
• Table 122. United States Viral Testing, by Virus Type USD Million (2014-2019)
• Table 123. Canada Viral Testing, by Type USD Million (2014-2019)
• Table 124. Canada Viral Testing, by Application USD Million (2014-2019)
• Table 125. Canada Viral Testing, by End-User USD Million (2014-2019)
• Table 126. Canada Viral Testing, by Virus Type USD Million (2014-2019)
• Table 127. Mexico Viral Testing, by Type USD Million (2014-2019)
• Table 128. Mexico Viral Testing, by Application USD Million (2014-2019)
• Table 129. Mexico Viral Testing, by End-User USD Million (2014-2019)
• Table 130. Mexico Viral Testing, by Virus Type USD Million (2014-2019)
• Table 131. Viral Testing Sales: by Type(K Units)
• Table 132. Viral Testing Sales Direct Fluorescent Antibody (DFA) Test , by Region K Units (2014-2019)
• Table 133. Viral Testing Sales Immunochromatographic Assay , by Region K Units (2014-2019)
• Table 134. Viral Testing Sales RT-PCR-Based Test , by Region K Units (2014-2019)
• Table 135. Viral Testing Sales Agglutination Assay , by Region K Units (2014-2019)
• Table 136. Viral Testing Sales Flow-Through Assay/Solid-Phase Assay , by Region K Units (2014-2019)
• Table 137. Viral Testing Sales: by Application(K Units)
• Table 138. Viral Testing Sales Individual , by Region K Units (2014-2019)
• Table 139. Viral Testing Sales Commercial , by Region K Units (2014-2019)
• Table 140. Viral Testing Sales: by End-User(K Units)
• Table 141. Viral Testing Sales Laboratories , by Region K Units (2014-2019)
• Table 142. Viral Testing Sales Hospitals , by Region K Units (2014-2019)
• Table 143. Viral Testing Sales Home Care Settings , by Region K Units (2014-2019)
• Table 144. Viral Testing Sales Academic Institutes , by Region K Units (2014-2019)
• Table 145. Viral Testing Sales: by Virus Type(K Units)
• Table 146. Viral Testing Sales Influenza , by Region K Units (2014-2019)
• Table 147. Viral Testing Sales Hepatitis , by Region K Units (2014-2019)
• Table 148. Viral Testing Sales HIV , by Region K Units (2014-2019)
• Table 149. Viral Testing Sales Measles , by Region K Units (2014-2019)
• Table 150. Viral Testing Sales Rubella , by Region K Units (2014-2019)
• Table 151. Viral Testing Sales Others , by Region K Units (2014-2019)
• Table 152. South America Viral Testing Sales, by Country K Units (2014-2019)
• Table 153. South America Viral Testing Sales, by Type K Units (2014-2019)
• Table 154. South America Viral Testing Sales, by Application K Units (2014-2019)
• Table 155. South America Viral Testing Sales, by End-User K Units (2014-2019)
• Table 156. South America Viral Testing Sales, by Virus Type K Units (2014-2019)
• Table 157. Brazil Viral Testing Sales, by Type K Units (2014-2019)
• Table 158. Brazil Viral Testing Sales, by Application K Units (2014-2019)
• Table 159. Brazil Viral Testing Sales, by End-User K Units (2014-2019)
• Table 160. Brazil Viral Testing Sales, by Virus Type K Units (2014-2019)
• Table 161. Argentina Viral Testing Sales, by Type K Units (2014-2019)
• Table 162. Argentina Viral Testing Sales, by Application K Units (2014-2019)
• Table 163. Argentina Viral Testing Sales, by End-User K Units (2014-2019)
• Table 164. Argentina Viral Testing Sales, by Virus Type K Units (2014-2019)
• Table 165. Rest of South America Viral Testing Sales, by Type K Units (2014-2019)
• Table 166. Rest of South America Viral Testing Sales, by Application K Units (2014-2019)
• Table 167. Rest of South America Viral Testing Sales, by End-User K Units (2014-2019)
• Table 168. Rest of South America Viral Testing Sales, by Virus Type K Units (2014-2019)
• Table 169. Asia Pacific Viral Testing Sales, by Country K Units (2014-2019)
• Table 170. Asia Pacific Viral Testing Sales, by Type K Units (2014-2019)
• Table 171. Asia Pacific Viral Testing Sales, by Application K Units (2014-2019)
• Table 172. Asia Pacific Viral Testing Sales, by End-User K Units (2014-2019)
• Table 173. Asia Pacific Viral Testing Sales, by Virus Type K Units (2014-2019)
• Table 174. China Viral Testing Sales, by Type K Units (2014-2019)
• Table 175. China Viral Testing Sales, by Application K Units (2014-2019)
• Table 176. China Viral Testing Sales, by End-User K Units (2014-2019)
• Table 177. China Viral Testing Sales, by Virus Type K Units (2014-2019)
• Table 178. Japan Viral Testing Sales, by Type K Units (2014-2019)
• Table 179. Japan Viral Testing Sales, by Application K Units (2014-2019)
• Table 180. Japan Viral Testing Sales, by End-User K Units (2014-2019)
• Table 181. Japan Viral Testing Sales, by Virus Type K Units (2014-2019)
• Table 182. India Viral Testing Sales, by Type K Units (2014-2019)
• Table 183. India Viral Testing Sales, by Application K Units (2014-2019)
• Table 184. India Viral Testing Sales, by End-User K Units (2014-2019)
• Table 185. India Viral Testing Sales, by Virus Type K Units (2014-2019)
• Table 186. South Korea Viral Testing Sales, by Type K Units (2014-2019)
• Table 187. South Korea Viral Testing Sales, by Application K Units (2014-2019)
• Table 188. South Korea Viral Testing Sales, by End-User K Units (2014-2019)
• Table 189. South Korea Viral Testing Sales, by Virus Type K Units (2014-2019)
• Table 190. Taiwan Viral Testing Sales, by Type K Units (2014-2019)
• Table 191. Taiwan Viral Testing Sales, by Application K Units (2014-2019)
• Table 192. Taiwan Viral Testing Sales, by End-User K Units (2014-2019)
• Table 193. Taiwan Viral Testing Sales, by Virus Type K Units (2014-2019)
• Table 194. Australia Viral Testing Sales, by Type K Units (2014-2019)
• Table 195. Australia Viral Testing Sales, by Application K Units (2014-2019)
• Table 196. Australia Viral Testing Sales, by End-User K Units (2014-2019)
• Table 197. Australia Viral Testing Sales, by Virus Type K Units (2014-2019)
• Table 198. Rest of Asia-Pacific Viral Testing Sales, by Type K Units (2014-2019)
• Table 199. Rest of Asia-Pacific Viral Testing Sales, by Application K Units (2014-2019)
• Table 200. Rest of Asia-Pacific Viral Testing Sales, by End-User K Units (2014-2019)
• Table 201. Rest of Asia-Pacific Viral Testing Sales, by Virus Type K Units (2014-2019)
• Table 202. Europe Viral Testing Sales, by Country K Units (2014-2019)
• Table 203. Europe Viral Testing Sales, by Type K Units (2014-2019)
• Table 204. Europe Viral Testing Sales, by Application K Units (2014-2019)
• Table 205. Europe Viral Testing Sales, by End-User K Units (2014-2019)
• Table 206. Europe Viral Testing Sales, by Virus Type K Units (2014-2019)
• Table 207. Germany Viral Testing Sales, by Type K Units (2014-2019)
• Table 208. Germany Viral Testing Sales, by Application K Units (2014-2019)
• Table 209. Germany Viral Testing Sales, by End-User K Units (2014-2019)
• Table 210. Germany Viral Testing Sales, by Virus Type K Units (2014-2019)
• Table 211. France Viral Testing Sales, by Type K Units (2014-2019)
• Table 212. France Viral Testing Sales, by Application K Units (2014-2019)
• Table 213. France Viral Testing Sales, by End-User K Units (2014-2019)
• Table 214. France Viral Testing Sales, by Virus Type K Units (2014-2019)
• Table 215. Italy Viral Testing Sales, by Type K Units (2014-2019)
• Table 216. Italy Viral Testing Sales, by Application K Units (2014-2019)
• Table 217. Italy Viral Testing Sales, by End-User K Units (2014-2019)
• Table 218. Italy Viral Testing Sales, by Virus Type K Units (2014-2019)
• Table 219. United Kingdom Viral Testing Sales, by Type K Units (2014-2019)
• Table 220. United Kingdom Viral Testing Sales, by Application K Units (2014-2019)
• Table 221. United Kingdom Viral Testing Sales, by End-User K Units (2014-2019)
• Table 222. United Kingdom Viral Testing Sales, by Virus Type K Units (2014-2019)
• Table 223. Netherlands Viral Testing Sales, by Type K Units (2014-2019)
• Table 224. Netherlands Viral Testing Sales, by Application K Units (2014-2019)
• Table 225. Netherlands Viral Testing Sales, by End-User K Units (2014-2019)
• Table 226. Netherlands Viral Testing Sales, by Virus Type K Units (2014-2019)
• Table 227. Rest of Europe Viral Testing Sales, by Type K Units (2014-2019)
• Table 228. Rest of Europe Viral Testing Sales, by Application K Units (2014-2019)
• Table 229. Rest of Europe Viral Testing Sales, by End-User K Units (2014-2019)
• Table 230. Rest of Europe Viral Testing Sales, by Virus Type K Units (2014-2019)
• Table 231. MEA Viral Testing Sales, by Country K Units (2014-2019)
• Table 232. MEA Viral Testing Sales, by Type K Units (2014-2019)
• Table 233. MEA Viral Testing Sales, by Application K Units (2014-2019)
• Table 234. MEA Viral Testing Sales, by End-User K Units (2014-2019)
• Table 235. MEA Viral Testing Sales, by Virus Type K Units (2014-2019)
• Table 236. Middle East Viral Testing Sales, by Type K Units (2014-2019)
• Table 237. Middle East Viral Testing Sales, by Application K Units (2014-2019)
• Table 238. Middle East Viral Testing Sales, by End-User K Units (2014-2019)
• Table 239. Middle East Viral Testing Sales, by Virus Type K Units (2014-2019)
• Table 240. Africa Viral Testing Sales, by Type K Units (2014-2019)
• Table 241. Africa Viral Testing Sales, by Application K Units (2014-2019)
• Table 242. Africa Viral Testing Sales, by End-User K Units (2014-2019)
• Table 243. Africa Viral Testing Sales, by Virus Type K Units (2014-2019)
• Table 244. North America Viral Testing Sales, by Country K Units (2014-2019)
• Table 245. North America Viral Testing Sales, by Type K Units (2014-2019)
• Table 246. North America Viral Testing Sales, by Application K Units (2014-2019)
• Table 247. North America Viral Testing Sales, by End-User K Units (2014-2019)
• Table 248. North America Viral Testing Sales, by Virus Type K Units (2014-2019)
• Table 249. United States Viral Testing Sales, by Type K Units (2014-2019)
• Table 250. United States Viral Testing Sales, by Application K Units (2014-2019)
• Table 251. United States Viral Testing Sales, by End-User K Units (2014-2019)
• Table 252. United States Viral Testing Sales, by Virus Type K Units (2014-2019)
• Table 253. Canada Viral Testing Sales, by Type K Units (2014-2019)
• Table 254. Canada Viral Testing Sales, by Application K Units (2014-2019)
• Table 255. Canada Viral Testing Sales, by End-User K Units (2014-2019)
• Table 256. Canada Viral Testing Sales, by Virus Type K Units (2014-2019)
• Table 257. Mexico Viral Testing Sales, by Type K Units (2014-2019)
• Table 258. Mexico Viral Testing Sales, by Application K Units (2014-2019)
• Table 259. Mexico Viral Testing Sales, by End-User K Units (2014-2019)
• Table 260. Mexico Viral Testing Sales, by Virus Type K Units (2014-2019)
• Table 261. Viral Testing: by Type(USD/Units)
• Table 262. Company Basic Information, Sales Area and Its Competitors
• Table 263. Company Basic Information, Sales Area and Its Competitors
• Table 264. Company Basic Information, Sales Area and Its Competitors
• Table 265. Company Basic Information, Sales Area and Its Competitors
• Table 266. Company Basic Information, Sales Area and Its Competitors
• Table 267. Company Basic Information, Sales Area and Its Competitors
• Table 268. Company Basic Information, Sales Area and Its Competitors
• Table 269. Company Basic Information, Sales Area and Its Competitors
• Table 270. Company Basic Information, Sales Area and Its Competitors
• Table 271. Company Basic Information, Sales Area and Its Competitors
• Table 272. Company Basic Information, Sales Area and Its Competitors
• Table 273. Company Basic Information, Sales Area and Its Competitors
• Table 274. Viral Testing: by Type(USD Million)
• Table 275. Viral Testing Direct Fluorescent Antibody (DFA) Test , by Region USD Million (2020-2025)
• Table 276. Viral Testing Immunochromatographic Assay , by Region USD Million (2020-2025)
• Table 277. Viral Testing RT-PCR-Based Test , by Region USD Million (2020-2025)
• Table 278. Viral Testing Agglutination Assay , by Region USD Million (2020-2025)
• Table 279. Viral Testing Flow-Through Assay/Solid-Phase Assay , by Region USD Million (2020-2025)
• Table 280. Viral Testing: by Application(USD Million)
• Table 281. Viral Testing Individual , by Region USD Million (2020-2025)
• Table 282. Viral Testing Commercial , by Region USD Million (2020-2025)
• Table 283. Viral Testing: by End-User(USD Million)
• Table 284. Viral Testing Laboratories , by Region USD Million (2020-2025)
• Table 285. Viral Testing Hospitals , by Region USD Million (2020-2025)
• Table 286. Viral Testing Home Care Settings , by Region USD Million (2020-2025)
• Table 287. Viral Testing Academic Institutes , by Region USD Million (2020-2025)
• Table 288. Viral Testing: by Virus Type(USD Million)
• Table 289. Viral Testing Influenza , by Region USD Million (2020-2025)
• Table 290. Viral Testing Hepatitis , by Region USD Million (2020-2025)
• Table 291. Viral Testing HIV , by Region USD Million (2020-2025)
• Table 292. Viral Testing Measles , by Region USD Million (2020-2025)
• Table 293. Viral Testing Rubella , by Region USD Million (2020-2025)
• Table 294. Viral Testing Others , by Region USD Million (2020-2025)
• Table 295. South America Viral Testing, by Country USD Million (2020-2025)
• Table 296. South America Viral Testing, by Type USD Million (2020-2025)
• Table 297. South America Viral Testing, by Application USD Million (2020-2025)
• Table 298. South America Viral Testing, by End-User USD Million (2020-2025)
• Table 299. South America Viral Testing, by Virus Type USD Million (2020-2025)
• Table 300. Brazil Viral Testing, by Type USD Million (2020-2025)
• Table 301. Brazil Viral Testing, by Application USD Million (2020-2025)
• Table 302. Brazil Viral Testing, by End-User USD Million (2020-2025)
• Table 303. Brazil Viral Testing, by Virus Type USD Million (2020-2025)
• Table 304. Argentina Viral Testing, by Type USD Million (2020-2025)
• Table 305. Argentina Viral Testing, by Application USD Million (2020-2025)
• Table 306. Argentina Viral Testing, by End-User USD Million (2020-2025)
• Table 307. Argentina Viral Testing, by Virus Type USD Million (2020-2025)
• Table 308. Rest of South America Viral Testing, by Type USD Million (2020-2025)
• Table 309. Rest of South America Viral Testing, by Application USD Million (2020-2025)
• Table 310. Rest of South America Viral Testing, by End-User USD Million (2020-2025)
• Table 311. Rest of South America Viral Testing, by Virus Type USD Million (2020-2025)
• Table 312. Asia Pacific Viral Testing, by Country USD Million (2020-2025)
• Table 313. Asia Pacific Viral Testing, by Type USD Million (2020-2025)
• Table 314. Asia Pacific Viral Testing, by Application USD Million (2020-2025)
• Table 315. Asia Pacific Viral Testing, by End-User USD Million (2020-2025)
• Table 316. Asia Pacific Viral Testing, by Virus Type USD Million (2020-2025)
• Table 317. China Viral Testing, by Type USD Million (2020-2025)
• Table 318. China Viral Testing, by Application USD Million (2020-2025)
• Table 319. China Viral Testing, by End-User USD Million (2020-2025)
• Table 320. China Viral Testing, by Virus Type USD Million (2020-2025)
• Table 321. Japan Viral Testing, by Type USD Million (2020-2025)
• Table 322. Japan Viral Testing, by Application USD Million (2020-2025)
• Table 323. Japan Viral Testing, by End-User USD Million (2020-2025)
• Table 324. Japan Viral Testing, by Virus Type USD Million (2020-2025)
• Table 325. India Viral Testing, by Type USD Million (2020-2025)
• Table 326. India Viral Testing, by Application USD Million (2020-2025)
• Table 327. India Viral Testing, by End-User USD Million (2020-2025)
• Table 328. India Viral Testing, by Virus Type USD Million (2020-2025)
• Table 329. South Korea Viral Testing, by Type USD Million (2020-2025)
• Table 330. South Korea Viral Testing, by Application USD Million (2020-2025)
• Table 331. South Korea Viral Testing, by End-User USD Million (2020-2025)
• Table 332. South Korea Viral Testing, by Virus Type USD Million (2020-2025)
• Table 333. Taiwan Viral Testing, by Type USD Million (2020-2025)
• Table 334. Taiwan Viral Testing, by Application USD Million (2020-2025)
• Table 335. Taiwan Viral Testing, by End-User USD Million (2020-2025)
• Table 336. Taiwan Viral Testing, by Virus Type USD Million (2020-2025)
• Table 337. Australia Viral Testing, by Type USD Million (2020-2025)
• Table 338. Australia Viral Testing, by Application USD Million (2020-2025)
• Table 339. Australia Viral Testing, by End-User USD Million (2020-2025)
• Table 340. Australia Viral Testing, by Virus Type USD Million (2020-2025)
• Table 341. Rest of Asia-Pacific Viral Testing, by Type USD Million (2020-2025)
• Table 342. Rest of Asia-Pacific Viral Testing, by Application USD Million (2020-2025)
• Table 343. Rest of Asia-Pacific Viral Testing, by End-User USD Million (2020-2025)
• Table 344. Rest of Asia-Pacific Viral Testing, by Virus Type USD Million (2020-2025)
• Table 345. Europe Viral Testing, by Country USD Million (2020-2025)
• Table 346. Europe Viral Testing, by Type USD Million (2020-2025)
• Table 347. Europe Viral Testing, by Application USD Million (2020-2025)
• Table 348. Europe Viral Testing, by End-User USD Million (2020-2025)
• Table 349. Europe Viral Testing, by Virus Type USD Million (2020-2025)
• Table 350. Germany Viral Testing, by Type USD Million (2020-2025)
• Table 351. Germany Viral Testing, by Application USD Million (2020-2025)
• Table 352. Germany Viral Testing, by End-User USD Million (2020-2025)
• Table 353. Germany Viral Testing, by Virus Type USD Million (2020-2025)
• Table 354. France Viral Testing, by Type USD Million (2020-2025)
• Table 355. France Viral Testing, by Application USD Million (2020-2025)
• Table 356. France Viral Testing, by End-User USD Million (2020-2025)
• Table 357. France Viral Testing, by Virus Type USD Million (2020-2025)
• Table 358. Italy Viral Testing, by Type USD Million (2020-2025)
• Table 359. Italy Viral Testing, by Application USD Million (2020-2025)
• Table 360. Italy Viral Testing, by End-User USD Million (2020-2025)
• Table 361. Italy Viral Testing, by Virus Type USD Million (2020-2025)
• Table 362. United Kingdom Viral Testing, by Type USD Million (2020-2025)
• Table 363. United Kingdom Viral Testing, by Application USD Million (2020-2025)
• Table 364. United Kingdom Viral Testing, by End-User USD Million (2020-2025)
• Table 365. United Kingdom Viral Testing, by Virus Type USD Million (2020-2025)
• Table 366. Netherlands Viral Testing, by Type USD Million (2020-2025)
• Table 367. Netherlands Viral Testing, by Application USD Million (2020-2025)
• Table 368. Netherlands Viral Testing, by End-User USD Million (2020-2025)
• Table 369. Netherlands Viral Testing, by Virus Type USD Million (2020-2025)
• Table 370. Rest of Europe Viral Testing, by Type USD Million (2020-2025)
• Table 371. Rest of Europe Viral Testing, by Application USD Million (2020-2025)
• Table 372. Rest of Europe Viral Testing, by End-User USD Million (2020-2025)
• Table 373. Rest of Europe Viral Testing, by Virus Type USD Million (2020-2025)
• Table 374. MEA Viral Testing, by Country USD Million (2020-2025)
• Table 375. MEA Viral Testing, by Type USD Million (2020-2025)
• Table 376. MEA Viral Testing, by Application USD Million (2020-2025)
• Table 377. MEA Viral Testing, by End-User USD Million (2020-2025)
• Table 378. MEA Viral Testing, by Virus Type USD Million (2020-2025)
• Table 379. Middle East Viral Testing, by Type USD Million (2020-2025)
• Table 380. Middle East Viral Testing, by Application USD Million (2020-2025)
• Table 381. Middle East Viral Testing, by End-User USD Million (2020-2025)
• Table 382. Middle East Viral Testing, by Virus Type USD Million (2020-2025)
• Table 383. Africa Viral Testing, by Type USD Million (2020-2025)
• Table 384. Africa Viral Testing, by Application USD Million (2020-2025)
• Table 385. Africa Viral Testing, by End-User USD Million (2020-2025)
• Table 386. Africa Viral Testing, by Virus Type USD Million (2020-2025)
• Table 387. North America Viral Testing, by Country USD Million (2020-2025)
• Table 388. North America Viral Testing, by Type USD Million (2020-2025)
• Table 389. North America Viral Testing, by Application USD Million (2020-2025)
• Table 390. North America Viral Testing, by End-User USD Million (2020-2025)
• Table 391. North America Viral Testing, by Virus Type USD Million (2020-2025)
• Table 392. United States Viral Testing, by Type USD Million (2020-2025)
• Table 393. United States Viral Testing, by Application USD Million (2020-2025)
• Table 394. United States Viral Testing, by End-User USD Million (2020-2025)
• Table 395. United States Viral Testing, by Virus Type USD Million (2020-2025)
• Table 396. Canada Viral Testing, by Type USD Million (2020-2025)
• Table 397. Canada Viral Testing, by Application USD Million (2020-2025)
• Table 398. Canada Viral Testing, by End-User USD Million (2020-2025)
• Table 399. Canada Viral Testing, by Virus Type USD Million (2020-2025)
• Table 400. Mexico Viral Testing, by Type USD Million (2020-2025)
• Table 401. Mexico Viral Testing, by Application USD Million (2020-2025)
• Table 402. Mexico Viral Testing, by End-User USD Million (2020-2025)
• Table 403. Mexico Viral Testing, by Virus Type USD Million (2020-2025)
• Table 404. Viral Testing Sales: by Type(K Units)
• Table 405. Viral Testing Sales Direct Fluorescent Antibody (DFA) Test , by Region K Units (2020-2025)
• Table 406. Viral Testing Sales Immunochromatographic Assay , by Region K Units (2020-2025)
• Table 407. Viral Testing Sales RT-PCR-Based Test , by Region K Units (2020-2025)
• Table 408. Viral Testing Sales Agglutination Assay , by Region K Units (2020-2025)
• Table 409. Viral Testing Sales Flow-Through Assay/Solid-Phase Assay , by Region K Units (2020-2025)
• Table 410. Viral Testing Sales: by Application(K Units)
• Table 411. Viral Testing Sales Individual , by Region K Units (2020-2025)
• Table 412. Viral Testing Sales Commercial , by Region K Units (2020-2025)
• Table 413. Viral Testing Sales: by End-User(K Units)
• Table 414. Viral Testing Sales Laboratories , by Region K Units (2020-2025)
• Table 415. Viral Testing Sales Hospitals , by Region K Units (2020-2025)
• Table 416. Viral Testing Sales Home Care Settings , by Region K Units (2020-2025)
• Table 417. Viral Testing Sales Academic Institutes , by Region K Units (2020-2025)
• Table 418. Viral Testing Sales: by Virus Type(K Units)
• Table 419. Viral Testing Sales Influenza , by Region K Units (2020-2025)
• Table 420. Viral Testing Sales Hepatitis , by Region K Units (2020-2025)
• Table 421. Viral Testing Sales HIV , by Region K Units (2020-2025)
• Table 422. Viral Testing Sales Measles , by Region K Units (2020-2025)
• Table 423. Viral Testing Sales Rubella , by Region K Units (2020-2025)
• Table 424. Viral Testing Sales Others , by Region K Units (2020-2025)
• Table 425. South America Viral Testing Sales, by Country K Units (2020-2025)
• Table 426. South America Viral Testing Sales, by Type K Units (2020-2025)
• Table 427. South America Viral Testing Sales, by Application K Units (2020-2025)
• Table 428. South America Viral Testing Sales, by End-User K Units (2020-2025)
• Table 429. South America Viral Testing Sales, by Virus Type K Units (2020-2025)
• Table 430. Brazil Viral Testing Sales, by Type K Units (2020-2025)
• Table 431. Brazil Viral Testing Sales, by Application K Units (2020-2025)
• Table 432. Brazil Viral Testing Sales, by End-User K Units (2020-2025)
• Table 433. Brazil Viral Testing Sales, by Virus Type K Units (2020-2025)
• Table 434. Argentina Viral Testing Sales, by Type K Units (2020-2025)
• Table 435. Argentina Viral Testing Sales, by Application K Units (2020-2025)
• Table 436. Argentina Viral Testing Sales, by End-User K Units (2020-2025)
• Table 437. Argentina Viral Testing Sales, by Virus Type K Units (2020-2025)
• Table 438. Rest of South America Viral Testing Sales, by Type K Units (2020-2025)
• Table 439. Rest of South America Viral Testing Sales, by Application K Units (2020-2025)
• Table 440. Rest of South America Viral Testing Sales, by End-User K Units (2020-2025)
• Table 441. Rest of South America Viral Testing Sales, by Virus Type K Units (2020-2025)
• Table 442. Asia Pacific Viral Testing Sales, by Country K Units (2020-2025)
• Table 443. Asia Pacific Viral Testing Sales, by Type K Units (2020-2025)
• Table 444. Asia Pacific Viral Testing Sales, by Application K Units (2020-2025)
• Table 445. Asia Pacific Viral Testing Sales, by End-User K Units (2020-2025)
• Table 446. Asia Pacific Viral Testing Sales, by Virus Type K Units (2020-2025)
• Table 447. China Viral Testing Sales, by Type K Units (2020-2025)
• Table 448. China Viral Testing Sales, by Application K Units (2020-2025)
• Table 449. China Viral Testing Sales, by End-User K Units (2020-2025)
• Table 450. China Viral Testing Sales, by Virus Type K Units (2020-2025)
• Table 451. Japan Viral Testing Sales, by Type K Units (2020-2025)
• Table 452. Japan Viral Testing Sales, by Application K Units (2020-2025)
• Table 453. Japan Viral Testing Sales, by End-User K Units (2020-2025)
• Table 454. Japan Viral Testing Sales, by Virus Type K Units (2020-2025)
• Table 455. India Viral Testing Sales, by Type K Units (2020-2025)
• Table 456. India Viral Testing Sales, by Application K Units (2020-2025)
• Table 457. India Viral Testing Sales, by End-User K Units (2020-2025)
• Table 458. India Viral Testing Sales, by Virus Type K Units (2020-2025)
• Table 459. South Korea Viral Testing Sales, by Type K Units (2020-2025)
• Table 460. South Korea Viral Testing Sales, by Application K Units (2020-2025)
• Table 461. South Korea Viral Testing Sales, by End-User K Units (2020-2025)
• Table 462. South Korea Viral Testing Sales, by Virus Type K Units (2020-2025)
• Table 463. Taiwan Viral Testing Sales, by Type K Units (2020-2025)
• Table 464. Taiwan Viral Testing Sales, by Application K Units (2020-2025)
• Table 465. Taiwan Viral Testing Sales, by End-User K Units (2020-2025)
• Table 466. Taiwan Viral Testing Sales, by Virus Type K Units (2020-2025)
• Table 467. Australia Viral Testing Sales, by Type K Units (2020-2025)
• Table 468. Australia Viral Testing Sales, by Application K Units (2020-2025)
• Table 469. Australia Viral Testing Sales, by End-User K Units (2020-2025)
• Table 470. Australia Viral Testing Sales, by Virus Type K Units (2020-2025)
• Table 471. Rest of Asia-Pacific Viral Testing Sales, by Type K Units (2020-2025)
• Table 472. Rest of Asia-Pacific Viral Testing Sales, by Application K Units (2020-2025)
• Table 473. Rest of Asia-Pacific Viral Testing Sales, by End-User K Units (2020-2025)
• Table 474. Rest of Asia-Pacific Viral Testing Sales, by Virus Type K Units (2020-2025)
• Table 475. Europe Viral Testing Sales, by Country K Units (2020-2025)
• Table 476. Europe Viral Testing Sales, by Type K Units (2020-2025)
• Table 477. Europe Viral Testing Sales, by Application K Units (2020-2025)
• Table 478. Europe Viral Testing Sales, by End-User K Units (2020-2025)
• Table 479. Europe Viral Testing Sales, by Virus Type K Units (2020-2025)
• Table 480. Germany Viral Testing Sales, by Type K Units (2020-2025)
• Table 481. Germany Viral Testing Sales, by Application K Units (2020-2025)
• Table 482. Germany Viral Testing Sales, by End-User K Units (2020-2025)
• Table 483. Germany Viral Testing Sales, by Virus Type K Units (2020-2025)
• Table 484. France Viral Testing Sales, by Type K Units (2020-2025)
• Table 485. France Viral Testing Sales, by Application K Units (2020-2025)
• Table 486. France Viral Testing Sales, by End-User K Units (2020-2025)
• Table 487. France Viral Testing Sales, by Virus Type K Units (2020-2025)
• Table 488. Italy Viral Testing Sales, by Type K Units (2020-2025)
• Table 489. Italy Viral Testing Sales, by Application K Units (2020-2025)
• Table 490. Italy Viral Testing Sales, by End-User K Units (2020-2025)
• Table 491. Italy Viral Testing Sales, by Virus Type K Units (2020-2025)
• Table 492. United Kingdom Viral Testing Sales, by Type K Units (2020-2025)
• Table 493. United Kingdom Viral Testing Sales, by Application K Units (2020-2025)
• Table 494. United Kingdom Viral Testing Sales, by End-User K Units (2020-2025)
• Table 495. United Kingdom Viral Testing Sales, by Virus Type K Units (2020-2025)
• Table 496. Netherlands Viral Testing Sales, by Type K Units (2020-2025)
• Table 497. Netherlands Viral Testing Sales, by Application K Units (2020-2025)
• Table 498. Netherlands Viral Testing Sales, by End-User K Units (2020-2025)
• Table 499. Netherlands Viral Testing Sales, by Virus Type K Units (2020-2025)
• Table 500. Rest of Europe Viral Testing Sales, by Type K Units (2020-2025)
• Table 501. Rest of Europe Viral Testing Sales, by Application K Units (2020-2025)
• Table 502. Rest of Europe Viral Testing Sales, by End-User K Units (2020-2025)
• Table 503. Rest of Europe Viral Testing Sales, by Virus Type K Units (2020-2025)
• Table 504. MEA Viral Testing Sales, by Country K Units (2020-2025)
• Table 505. MEA Viral Testing Sales, by Type K Units (2020-2025)
• Table 506. MEA Viral Testing Sales, by Application K Units (2020-2025)
• Table 507. MEA Viral Testing Sales, by End-User K Units (2020-2025)
• Table 508. MEA Viral Testing Sales, by Virus Type K Units (2020-2025)
• Table 509. Middle East Viral Testing Sales, by Type K Units (2020-2025)
• Table 510. Middle East Viral Testing Sales, by Application K Units (2020-2025)
• Table 511. Middle East Viral Testing Sales, by End-User K Units (2020-2025)
• Table 512. Middle East Viral Testing Sales, by Virus Type K Units (2020-2025)
• Table 513. Africa Viral Testing Sales, by Type K Units (2020-2025)
• Table 514. Africa Viral Testing Sales, by Application K Units (2020-2025)
• Table 515. Africa Viral Testing Sales, by End-User K Units (2020-2025)
• Table 516. Africa Viral Testing Sales, by Virus Type K Units (2020-2025)
• Table 517. North America Viral Testing Sales, by Country K Units (2020-2025)
• Table 518. North America Viral Testing Sales, by Type K Units (2020-2025)
• Table 519. North America Viral Testing Sales, by Application K Units (2020-2025)
• Table 520. North America Viral Testing Sales, by End-User K Units (2020-2025)
• Table 521. North America Viral Testing Sales, by Virus Type K Units (2020-2025)
• Table 522. United States Viral Testing Sales, by Type K Units (2020-2025)
• Table 523. United States Viral Testing Sales, by Application K Units (2020-2025)
• Table 524. United States Viral Testing Sales, by End-User K Units (2020-2025)
• Table 525. United States Viral Testing Sales, by Virus Type K Units (2020-2025)
• Table 526. Canada Viral Testing Sales, by Type K Units (2020-2025)
• Table 527. Canada Viral Testing Sales, by Application K Units (2020-2025)
• Table 528. Canada Viral Testing Sales, by End-User K Units (2020-2025)
• Table 529. Canada Viral Testing Sales, by Virus Type K Units (2020-2025)
• Table 530. Mexico Viral Testing Sales, by Type K Units (2020-2025)
• Table 531. Mexico Viral Testing Sales, by Application K Units (2020-2025)
• Table 532. Mexico Viral Testing Sales, by End-User K Units (2020-2025)
• Table 533. Mexico Viral Testing Sales, by Virus Type K Units (2020-2025)
• Table 534. Viral Testing: by Type(USD/Units)
• Table 535. Research Programs/Design for This Report
• Table 536. Key Data Information from Secondary Sources
• Table 537. Key Data Information from Primary Sources

• Figure 1. Porters Five Forces
• Figure 2. Supply/Value Chain
• Figure 3. PESTEL analysis
• Figure 4. Global Viral Testing: by Type USD Million (2014-2019)
• Figure 5. Global Viral Testing: by Application USD Million (2014-2019)
• Figure 6. Global Viral Testing: by End-User USD Million (2014-2019)
• Figure 7. Global Viral Testing: by Virus Type USD Million (2014-2019)
• Figure 8. South America Viral Testing Share (%), by Country
• Figure 9. Asia Pacific Viral Testing Share (%), by Country
• Figure 10. Europe Viral Testing Share (%), by Country
• Figure 11. MEA Viral Testing Share (%), by Country
• Figure 12. North America Viral Testing Share (%), by Country
• Figure 13. Global Viral Testing: by Type K Units (2014-2019)
• Figure 14. Global Viral Testing: by Application K Units (2014-2019)
• Figure 15. Global Viral Testing: by End-User K Units (2014-2019)
• Figure 16. Global Viral Testing: by Virus Type K Units (2014-2019)
• Figure 17. South America Viral Testing Share (%), by Country
• Figure 18. Asia Pacific Viral Testing Share (%), by Country
• Figure 19. Europe Viral Testing Share (%), by Country
• Figure 20. MEA Viral Testing Share (%), by Country
• Figure 21. North America Viral Testing Share (%), by Country
• Figure 22. Global Viral Testing: by Type USD/Units (2014-2019)
• Figure 23. Global Viral Testing share by Players 2019 (%)
• Figure 24. Global Viral Testing share by Players (Top 3) 2019(%)
• Figure 25. Global Viral Testing share by Players (Top 5) 2019(%)
• Figure 26. BCG Matrix for key Companies
• Figure 27. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
• Figure 28. Roche Holding AG (Switzerland) Revenue: by Geography 2019
• Figure 29. Agilent Technologies (United States) Revenue, Net Income and Gross profit
• Figure 30. Agilent Technologies (United States) Revenue: by Geography 2019
• Figure 31. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
• Figure 32. Thermo Fisher Scientific (United States) Revenue: by Geography 2019
• Figure 33. QIAGEN International (Netherlands) Revenue, Net Income and Gross profit
• Figure 34. QIAGEN International (Netherlands) Revenue: by Geography 2019
• Figure 35. Lonza Group AG (Switzerland) Revenue, Net Income and Gross profit
• Figure 36. Lonza Group AG (Switzerland) Revenue: by Geography 2019
• Figure 37. Wuxi Pharmatech (Cayman) Revenue, Net Income and Gross profit
• Figure 38. Wuxi Pharmatech (Cayman) Revenue: by Geography 2019
• Figure 39. Merck (United States) Revenue, Net Income and Gross profit
• Figure 40. Merck (United States) Revenue: by Geography 2019
• Figure 41. Eurofins Scientific (Luxembourg) Revenue, Net Income and Gross profit
• Figure 42. Eurofins Scientific (Luxembourg) Revenue: by Geography 2019
• Figure 43. General Electric (United States) Revenue, Net Income and Gross profit
• Figure 44. General Electric (United States) Revenue: by Geography 2019
• Figure 45. Danaher Corporation (United States) Revenue, Net Income and Gross profit
• Figure 46. Danaher Corporation (United States) Revenue: by Geography 2019
• Figure 47. Bio-Rad Laboratories (United States) Revenue, Net Income and Gross profit
• Figure 48. Bio-Rad Laboratories (United States) Revenue: by Geography 2019
• Figure 49. BD (United States) Revenue, Net Income and Gross profit
• Figure 50. BD (United States) Revenue: by Geography 2019
• Figure 51. Global Viral Testing: by Type USD Million (2020-2025)
• Figure 52. Global Viral Testing: by Application USD Million (2020-2025)
• Figure 53. Global Viral Testing: by End-User USD Million (2020-2025)
• Figure 54. Global Viral Testing: by Virus Type USD Million (2020-2025)
• Figure 55. South America Viral Testing Share (%), by Country
• Figure 56. Asia Pacific Viral Testing Share (%), by Country
• Figure 57. Europe Viral Testing Share (%), by Country
• Figure 58. MEA Viral Testing Share (%), by Country
• Figure 59. North America Viral Testing Share (%), by Country
• Figure 60. Global Viral Testing: by Type K Units (2020-2025)
• Figure 61. Global Viral Testing: by Application K Units (2020-2025)
• Figure 62. Global Viral Testing: by End-User K Units (2020-2025)
• Figure 63. Global Viral Testing: by Virus Type K Units (2020-2025)
• Figure 64. South America Viral Testing Share (%), by Country
• Figure 65. Asia Pacific Viral Testing Share (%), by Country
• Figure 66. Europe Viral Testing Share (%), by Country
• Figure 67. MEA Viral Testing Share (%), by Country
• Figure 68. North America Viral Testing Share (%), by Country
• Figure 69. Global Viral Testing: by Type USD/Units (2020-2025)

• Roche Holding AG (Switzerland)
• Agilent Technologies (United States)
• Thermo Fisher Scientific (United States)
• QIAGEN International (Netherlands)
• Lonza Group AG (Switzerland)
• Wuxi Pharmatech (Cayman)
• Merck (United States)
• Eurofins Scientific (Luxembourg)
• General Electric (United States)
• Danaher Corporation (United States)
• Bio-Rad Laboratories (United States)
• BD (United States)